Ignite Creation Date:
2025-12-24 @ 10:51 PM
Ignite Modification Date:
2025-12-28 @ 10:35 PM
Study NCT ID:
NCT00617669
Status:
COMPLETED
Last Update Posted:
2012-09-10
First Post:
2008-01-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-01
Start Date Type:
None
Primary Completion Date:
2011-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-07
Completion Date Type:
ACTUAL
First Submit Date:
2008-01-24
First Submit QC Date:
None
Study First Post Date:
2008-02-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2012-04-26
Results First Submit QC Date:
None
Results First Post Date:
2012-05-31
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-09-04
Last Update Post Date:
2012-09-10
Last Update Post Date Type:
ESTIMATED